The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis

• Autor(a) principal: Fragoso, Yara Dadalti
• Data de Publicação: 2014
• Outros Autores: Arruda, Christian Cardoso, Arruda, Walter Oleschko, Brooks, Joseph Bruno Bidin, Damasceno, Alfredo, Damasceno, Carlos Augusto de Albuquerque, Finkelsztejn, Alessandro, Finkelsztejn, Juliana, Gama, Paulo Diniz da, Giacomo, Maria Cristina Brandão, Gomes, Sidney, Goncalves, Marcus Vinicius Magno, Matta, Andre Palma da Cunha, Morais, Marilia Manprim de, Oliveira, Enedina Maria Lobato de [UNIFESP], Ribeiro, Yuna, Sato, Henry Koiti, Tauil, Carlos Bernardo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1590/0004-282X20140102; http://repositorio.unifesp.br/handle/11600/8562
• topic: multiple sclerosis; fingolimod; bradycardia; adverse event; esclerose múltipla; fingolimode; bradicardia; evento adverso

Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.